Q3 2025 Earnings Estimate for Wave Life Sciences Ltd. Issued By Leerink Partnrs (NASDAQ:WVE)

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for Wave Life Sciences in a report released on Tuesday, September 24th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.38). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.43) EPS and FY2026 earnings at ($0.93) EPS.

Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.09). The business had revenue of $19.69 million for the quarter, compared to analyst estimates of $24.80 million. Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. During the same period in the prior year, the business earned ($0.20) EPS.

WVE has been the topic of several other reports. Mizuho reissued an “outperform” rating and set a $19.00 target price on shares of Wave Life Sciences in a research note on Tuesday, June 25th. JPMorgan Chase & Co. initiated coverage on Wave Life Sciences in a research note on Monday, September 9th. They issued an “overweight” rating and a $10.00 target price for the company. HC Wainwright upped their price target on Wave Life Sciences from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, B. Riley began coverage on Wave Life Sciences in a report on Thursday, September 19th. They issued a “buy” rating and a $11.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Wave Life Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $13.38.

Wave Life Sciences Stock Down 11.0 %

Shares of WVE stock opened at $8.02 on Friday. The firm has a 50 day moving average of $5.98 and a 200-day moving average of $5.84. The company has a market cap of $982.25 million, a price-to-earnings ratio of -15.42 and a beta of -1.13. Wave Life Sciences has a 52 week low of $3.50 and a 52 week high of $9.92.

Insider Activity at Wave Life Sciences

In related news, CEO Paul Bolno sold 48,366 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $5.78, for a total transaction of $279,555.48. Following the transaction, the chief executive officer now directly owns 359,059 shares of the company’s stock, valued at $2,075,361.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 29.10% of the stock is owned by insiders.

Institutional Trading of Wave Life Sciences

A number of institutional investors have recently modified their holdings of the business. Driehaus Capital Management LLC lifted its position in Wave Life Sciences by 62.2% during the second quarter. Driehaus Capital Management LLC now owns 908,096 shares of the company’s stock valued at $4,531,000 after purchasing an additional 348,300 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Wave Life Sciences by 13.6% in the 2nd quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after acquiring an additional 1,905 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Wave Life Sciences by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 139,790 shares of the company’s stock worth $698,000 after purchasing an additional 4,914 shares during the last quarter. Millennium Management LLC raised its stake in shares of Wave Life Sciences by 1.8% during the second quarter. Millennium Management LLC now owns 1,664,300 shares of the company’s stock valued at $8,305,000 after acquiring an additional 28,690 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Wave Life Sciences by 26.3% during the 2nd quarter. AQR Capital Management LLC now owns 33,529 shares of the company’s stock valued at $167,000 after purchasing an additional 6,973 shares during the last quarter. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.